Trial Profile
High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Nov 2021
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary) ; HMG-CoA reductase inhibitors
- Indications Acute coronary syndromes; Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms HUYGENS
- Sponsors Amgen
- 27 Aug 2021 According to an Amgen media release, data from this trial are being presented during an oral presentation at ESC Congress 2021, organized by the European Society of Cardiology.
- 27 Aug 2021 Results published in an Amgen Media Release.
- 27 Aug 2021 According to an Amgen media release, Stephen J. Nicholls is the first author of the study.